RU2121835C1 - Фармацевтическая композиция - Google Patents

Фармацевтическая композиция Download PDF

Info

Publication number
RU2121835C1
RU2121835C1 RU92004564A RU92004564A RU2121835C1 RU 2121835 C1 RU2121835 C1 RU 2121835C1 RU 92004564 A RU92004564 A RU 92004564A RU 92004564 A RU92004564 A RU 92004564A RU 2121835 C1 RU2121835 C1 RU 2121835C1
Authority
RU
Russia
Prior art keywords
composition
carbonate
composition according
sodium
fluvastatin
Prior art date
Application number
RU92004564A
Other languages
English (en)
Russian (ru)
Other versions
RU92004564A (ru
Inventor
Балахандра Кабади Мохан
Виктор Вивилеччиа Ричард
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36808687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2121835(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU92004564A publication Critical patent/RU92004564A/ru
Application granted granted Critical
Publication of RU2121835C1 publication Critical patent/RU2121835C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU92004564A 1991-12-12 1992-12-11 Фармацевтическая композиция RU2121835C1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80566791A 1991-12-12 1991-12-12
US07/803667 1991-12-12
US07/805.667 1991-12-12
CN93100650A CN1041794C (zh) 1991-12-12 1993-01-30 含有一种β－羟基－β－甲基戊二酸单酰辅酶A还原酶抑制剂的稳定的药物组合物

Publications (2)

Publication Number Publication Date
RU92004564A RU92004564A (ru) 1995-05-10
RU2121835C1 true RU2121835C1 (ru) 1998-11-20

Family

ID=36808687

Family Applications (1)

Application Number Title Priority Date Filing Date
RU92004564A RU2121835C1 (ru) 1991-12-12 1992-12-11 Фармацевтическая композиция

Country Status (31)

Country Link
US (1) US5356896A (enExample)
EP (1) EP0547000B1 (enExample)
JP (1) JP2774037B2 (enExample)
KR (1) KR100253824B1 (enExample)
CN (1) CN1041794C (enExample)
AT (1) AT401870B (enExample)
AU (1) AU661075B2 (enExample)
CA (1) CA2085037C (enExample)
CH (1) CH684309A5 (enExample)
CY (1) CY1994A (enExample)
CZ (1) CZ287776B6 (enExample)
DE (1) DE4240430B4 (enExample)
DK (1) DK0547000T3 (enExample)
ES (1) ES2142819T3 (enExample)
FI (1) FI114284B (enExample)
FR (1) FR2684876B1 (enExample)
GB (1) GB2262229B (enExample)
GR (1) GR3032929T3 (enExample)
HK (1) HK25597A (enExample)
HU (2) HU9203780D0 (enExample)
IL (1) IL104041A (enExample)
IT (1) IT1256698B (enExample)
LU (1) LU88201A1 (enExample)
MX (1) MX9207152A (enExample)
NO (1) NO302099B1 (enExample)
NZ (1) NZ245421A (enExample)
PT (1) PT547000E (enExample)
RO (1) RO111542B1 (enExample)
RU (1) RU2121835C1 (enExample)
SK (1) SK281710B6 (enExample)
ZA (1) ZA929642B (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2152209C1 (ru) * 1994-05-13 2000-07-10 Егис Гиогисзергуар Р.Т. Гемфиброзил-содержащие фармацевтические композиции
RU2206324C1 (ru) * 2000-01-26 2003-06-20 Астразенека Аб Фармацевтические композиции, содержащие ингибитор hmg редуктазы
RU2227019C2 (ru) * 1998-12-16 2004-04-20 Лек Фармасьютикал Энд Кемикал Компани Д.Д. Твердый фармацевтический препарат, содержащий ингибитор hmg-coa-редуктазы
RU2246943C2 (ru) * 2000-06-09 2005-02-27 Лек Фармасьютикал Энд Кемикал Компани Д.Д. Стабилизированная фармацевтически эффективная композиция и фармацевтический препарат, ее содержащий
RU2297223C2 (ru) * 2000-04-13 2007-04-20 Новартис Аг Содержащие флувастатин фармацевтические композиции
RU2334738C2 (ru) * 2001-08-03 2008-09-27 Циба Спешиалти Кемикэлз Холдинг Инк. Кристаллические формы
RU2361582C2 (ru) * 2003-06-25 2009-07-20 Новартис Аг Таблетка, содержащая флувастатин и кармеллозу кальция
RU2469707C2 (ru) * 2006-09-27 2012-12-20 Новартис Аг Фармацевтические композиции, содержащие нилотиниб или его соль
RU2487703C2 (ru) * 2006-09-26 2013-07-20 Новартис Аг Фармацевтические композиции, включающие модулятор s1р
US8507527B2 (en) 2004-12-27 2013-08-13 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300361B1 (en) * 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
DE4243279A1 (de) * 1992-12-21 1994-06-23 Bayer Ag Substituierte Triole
US5399356A (en) * 1994-03-24 1995-03-21 The Procter & Gamble Company Process for making solid dose forms containing bismuth
US6107462A (en) * 1995-08-17 2000-08-22 The Regents Of The University Of California Genes and proteins controlling cholesterol synthesis
CZ288545B6 (cs) * 1995-12-22 2001-07-11 Kowa Company, Ltd. Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
CA2577233C (en) * 1996-04-05 2009-08-18 Takeda Pharmaceutical Company Limited Pharmaceutical composition containing angiotensin ii antagonist
CN1221398A (zh) * 1996-04-16 1999-06-30 拜尔公司 甘露糖醇及其制备
JP3126683B2 (ja) 1996-04-16 2001-01-22 武田薬品工業株式会社 Ｄ−マンニトールおよびその製造法
PT907639E (pt) * 1996-06-24 2003-06-30 Novartis Ag Compostos polimorficos
SE9603668D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions
DE19725391A1 (de) * 1997-06-16 1998-12-17 Bayer Ag Verfahren zur Herstellung von Arzneimittel, enthaltend HMG-CoA-Reduktase-Inhibitoren
US6465477B1 (en) * 1997-08-18 2002-10-15 Kowa Company, Ltd. Stable pharmaceutical composition
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
HK1042856B (zh) 1998-11-20 2007-07-27 Skyepharma Canada Inc. 可分散的磷脂稳定的微粒
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
EP1036563A1 (en) * 1999-03-08 2000-09-20 MERCK & CO. INC. Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
WO2000053173A1 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
WO2001032161A2 (en) * 1999-11-04 2001-05-10 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
JP2003523330A (ja) 2000-02-04 2003-08-05 チルドレンズ・ホスピタル・リサーチ・ファウンデイション アテローム性動脈硬化症および関連疾患のための脂質加水分解治療
AU2001246883B2 (en) * 2000-04-11 2004-08-12 Sankyo Company, Limited Stabilized pharmaceutical compositions containing calcium channel blockers
GB0011163D0 (en) * 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
US6743926B2 (en) * 2000-05-26 2004-06-01 Ciba Specialty Chemicals Corporation Process for the preparation of indole derivatives and intermediates of the process
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
WO2001093859A1 (en) 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stable pharmaceutical product and formulation
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
EP1379167A1 (en) 2001-04-06 2004-01-14 Medic4all Inc. A physiological monitoring system for a computational device of a human subject
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
EP1390030A1 (en) * 2001-05-31 2004-02-25 Cellegy Pharmaceuticals, Inc Store operated calcium influx inhibitors and methods of use
EP1404303A4 (en) * 2001-06-21 2006-03-15 Andrx Pharmaceuticals Inc STABLE PHARMACEUTICAL COMPOSITIONS BASED ON PRAVASTATIN
JP4638148B2 (ja) 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
AU2003245736A1 (en) * 2002-02-14 2003-09-04 Ranbaxy Laboratories Limited Formulations of atorvastatin stabilized with alkali metal additions
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
EP2322160A1 (en) 2002-03-04 2011-05-18 Merck HDAC Research, LLC Methods of inducing terminal differentiation
WO2003088900A2 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Solid forms of salts with tyrosine kinase activity
WO2003094856A2 (en) 2002-05-09 2003-11-20 The Brigham And Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker and therapeutic target
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
ATE409476T1 (de) * 2002-06-13 2008-10-15 Novartis Pharma Gmbh Calciumsalze von statinen aus indol
US20040006109A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20040198800A1 (en) * 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
JP2006523613A (ja) * 2002-12-20 2006-10-19 エスティ．ジェイムス アソシエイト エルエルシー／フェイバー リサーチ シリーズ 徐放性医薬投与のための被覆粒子
CA2508840A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
JP2006520810A (ja) * 2003-03-17 2006-09-14 日本たばこ産業株式会社 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US7166638B2 (en) * 2003-05-27 2007-01-23 Nicox S.A. Statin derivatives
BRPI0410840A (pt) 2003-05-30 2006-07-04 Ranbaxy Lab Ltd derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
EP1726583A3 (en) * 2003-06-18 2007-05-09 Teva Pharmaceutical Industries Ltd Fluvastatin sodium crystal form LXXIX, processes for preparing it, compositions containing it and methods of using it.
JP2007077174A (ja) * 2003-06-25 2007-03-29 Novartis Ag フルバスタチン含有錠剤
GB2404336A (en) * 2003-07-30 2005-02-02 Cipla Ltd Stabilisation of therapeutic agents using a carbonate salt of an amino acid, preferably in the presence of a saccharide, & pharmaceutical compositions thereof
CN1839114A (zh) 2003-08-21 2006-09-27 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2005053683A1 (en) * 2003-11-26 2005-06-16 Duke University A method of preventing or treating glaucoma
ATE535614T1 (de) 2003-12-30 2011-12-15 Kowa Co Screening-verfahren fuer gamma-sekretase- inhibitoren
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
AU2005271413A1 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
KR20070052760A (ko) * 2004-08-06 2007-05-22 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 페노피브레이트 제제 및 관련된 치료방법
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
EP2927693A1 (en) 2004-10-06 2015-10-07 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
ES2255426B1 (es) 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
EP1827421B1 (en) 2004-12-09 2017-09-27 Merck Sharp & Dohme Corp. Estrogen receptor modulators
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
AP2764A (en) * 2005-01-31 2013-09-30 Mylan Lab Inc Hydroxylated nebivolol metabolites
CN104188952A (zh) 2005-03-02 2014-12-10 默沙东公司 抑制组织蛋白酶k的组合物
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
KR101213345B1 (ko) * 2005-04-28 2012-12-17 에자이 알앤드디 매니지먼트 가부시키가이샤 항치매약을 함유하는 조성물
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
CA2610694A1 (en) 2005-05-31 2006-12-07 Mylan Laboratories, Inc. Compositions comrising nebivolol
ATE548035T1 (de) 2005-07-11 2012-03-15 Cortria Corp Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
CA2615941A1 (en) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US20090247603A1 (en) * 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1905424A3 (en) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2642195A1 (en) * 2006-02-24 2007-09-07 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium pharmaceutical compositions
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
PE20080359A1 (es) 2006-04-19 2008-06-06 Novartis Ag Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r
EP2302395B1 (en) 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
ES2532595T3 (es) 2006-08-30 2015-03-30 Kyushu University, National University Corporation Composición farmacéutica que contiene una nanopartícula de estatina encapsulada
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP1911441A3 (en) * 2006-10-11 2008-08-06 Lupin Limited Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20080132560A1 (en) * 2006-11-21 2008-06-05 San-Laung Chow Solid dispersion composition
US20110052688A1 (en) * 2006-11-21 2011-03-03 San-Laung Chow Solid dispersion composition
GEP20115337B (en) 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
EA019951B1 (ru) 2007-03-01 2014-07-30 Новартис Аг Ингибиторы киназы pim и способы их применения
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
AU2008236616A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
EP2891885A3 (en) 2007-04-18 2015-10-14 Health Diagnostic Laboratory, Inc. Diabetes-related biomarkers and methods of use thereof
CA2685967A1 (en) 2007-05-21 2008-11-21 Novartis Ag Csf-1r inhibitors, compositions, and methods of use
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN101855344B (zh) 2007-07-26 2015-12-09 安姆根有限公司 修饰的卵磷脂-胆固醇酰基转移酶
ES2413504T3 (es) 2007-12-21 2013-07-16 Ligand Pharmaceuticals Inc. Moduladores selectivos del receptor de andrógeno (SARM) y usos de los mismos
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
HRP20180077T1 (hr) * 2008-06-27 2018-02-23 Krka, Tovarna Zdravil D.D., Novo Mesto Farmaceutski sastav koji sadrži statin
JP2011525901A (ja) * 2008-06-27 2011-09-29 アブディ イブラヒム イラク サナイ ベ ティカレット アノニム シルケティ ロスバスタチンカルシウム含有医薬組成物
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
JP2012096998A (ja) * 2009-02-27 2012-05-24 Kowa Co 安定なカプセル製剤及びその製造方法
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
MY174452A (en) 2009-10-14 2020-04-19 Schering Corp Substituted piperidines that increase p53 activity and the uses thereof
CN102665764A (zh) * 2009-12-22 2012-09-12 Fmc有限公司 可用作可再压实药物赋形剂的微晶纤维素和碳酸钙组合物
KR20120139723A (ko) 2010-02-01 2012-12-27 더 호스피탈 포 식 칠드런 재발협착증의 치료 및 예방을 위한 원격 허혈 처치
CN102939054A (zh) 2010-03-31 2013-02-20 儿童医院 远端缺血处理改进心肌梗死之后的结果的用途
KR20130040878A (ko) 2010-04-08 2013-04-24 더 호스피탈 포 식 칠드런 외상성 손상을 위한 원격 허혈 처치의 사용
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2803558C (en) * 2010-06-30 2018-05-29 Mochida Pharmaceutical Co., Ltd. .omega.3 fatty acid compound preparation
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
AU2011287955B2 (en) * 2010-08-04 2015-07-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
EP3587574B1 (en) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
US20130210860A1 (en) 2010-10-06 2013-08-15 Kowa Co., Ltd. Prophylactic and/or therapeutic agent against lymphedema
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2698159A4 (en) * 2011-04-12 2014-11-05 Sawai Seiyaku Kk PITAVASTATE-CONTAINING PREPARATION AND METHOD OF MANUFACTURING THEREOF
CA2833009A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2012153181A1 (en) * 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
KR101830977B1 (ko) * 2011-06-30 2018-02-21 한미약품 주식회사 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
AU2012347540A1 (en) 2011-12-08 2014-06-26 Amgen Inc. Agonistic human LCAT antigen binding proteins and their use in therapy
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
AU2013296803B2 (en) 2012-08-01 2018-03-08 Eric Ostertag Free flowing, frozen compositions comprising a therapeutic agent
KR101461841B1 (ko) 2012-08-08 2014-11-13 코와 가부시키가이샤 의약
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
AR094116A1 (es) 2012-12-20 2015-07-08 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de hdm2
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2014153541A1 (en) 2013-03-21 2014-09-25 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
CN104069502B (zh) * 2013-03-29 2018-02-16 北京罗诺强施医药技术研发中心有限公司 复合骨架材料及其药物组合物
RO129060B1 (ro) * 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
KR20160065854A (ko) 2013-10-08 2016-06-09 머크 샤프 앤드 돔 코포레이션 카텝신 시스테인 프로테아제 억제제
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
EP3613418A1 (en) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015185240A1 (en) 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
EP3219318A4 (en) 2014-11-11 2018-07-11 Shionogi & Co., Ltd. Multi-layered tablet containing drug unstable with respect to light
RU2018119121A (ru) 2015-10-27 2019-11-28 Юпраксия Фармасьютикалз Инк. Лекарственные формы местных анастетиков с замедленным высвобождением
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
RU2648445C1 (ru) * 2016-11-03 2018-03-26 Светлана Асылхановна Астафьева 6-(3,3- диметил-3,4-дигидроизохинолин-1-ил) аминогексановая кислота и фармацевтическая композиция на ёе основе, обладающие анальгетической активностью
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
KR101954568B1 (ko) * 2018-01-22 2019-03-05 한미약품 주식회사 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833355A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
BR112021020864A2 (pt) 2019-04-19 2021-12-14 Ligand Pharm Inc Formas cristalinas e métodos de produção de formas cristalinas de um composto
WO2021126729A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20230108114A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
AU2020408148B2 (en) 2019-12-17 2025-04-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
AU2024228641A1 (en) 2023-03-02 2025-07-24 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865935A (en) * 1972-08-10 1975-02-11 Abbott Lab Tableting of erythromycin base
US3952096A (en) * 1973-06-15 1976-04-20 Bristol-Myers Company Mixture of calcium carbonate and calcium-α-p-chlorophenoxyisobutyrate as an antihyperlipemic agent
US3891755A (en) * 1973-07-11 1975-06-24 Abbott Lab Dosage formulation for erythromycin cetyl sulfate
US4342767A (en) * 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
WO1984002131A1 (fr) * 1982-11-22 1984-06-07 Sandoz Ag Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques
US4744987A (en) * 1985-03-08 1988-05-17 Fmc Corporation Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US4997658A (en) * 1988-11-21 1991-03-05 Merck & Co., Inc. Method for enhancing the lowering of plasma cholesterol levels
US4933165A (en) * 1989-01-18 1990-06-12 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5004651A (en) * 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
CA2042526A1 (en) * 1990-06-11 1991-12-12 Adeoye Y. Olukotun Method for preventing a second heart attack employing an hmg coa reductase inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2152209C1 (ru) * 1994-05-13 2000-07-10 Егис Гиогисзергуар Р.Т. Гемфиброзил-содержащие фармацевтические композиции
RU2227019C2 (ru) * 1998-12-16 2004-04-20 Лек Фармасьютикал Энд Кемикал Компани Д.Д. Твердый фармацевтический препарат, содержащий ингибитор hmg-coa-редуктазы
RU2206324C1 (ru) * 2000-01-26 2003-06-20 Астразенека Аб Фармацевтические композиции, содержащие ингибитор hmg редуктазы
RU2297223C2 (ru) * 2000-04-13 2007-04-20 Новартис Аг Содержащие флувастатин фармацевтические композиции
RU2246943C2 (ru) * 2000-06-09 2005-02-27 Лек Фармасьютикал Энд Кемикал Компани Д.Д. Стабилизированная фармацевтически эффективная композиция и фармацевтический препарат, ее содержащий
RU2334738C2 (ru) * 2001-08-03 2008-09-27 Циба Спешиалти Кемикэлз Холдинг Инк. Кристаллические формы
RU2361582C2 (ru) * 2003-06-25 2009-07-20 Новартис Аг Таблетка, содержащая флувастатин и кармеллозу кальция
US8507527B2 (en) 2004-12-27 2013-08-13 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
RU2487703C2 (ru) * 2006-09-26 2013-07-20 Новартис Аг Фармацевтические композиции, включающие модулятор s1р
RU2469707C2 (ru) * 2006-09-27 2012-12-20 Новартис Аг Фармацевтические композиции, содержащие нилотиниб или его соль

Also Published As

Publication number Publication date
CZ287776B6 (cs) 2001-01-17
GB9225659D0 (en) 1993-01-27
FR2684876A1 (fr) 1993-06-18
IT1256698B (it) 1995-12-12
FI925615A0 (fi) 1992-12-10
ZA929642B (en) 1994-06-13
FR2684876B1 (fr) 1995-05-05
ITRM920870A0 (it) 1992-12-04
HU9203780D0 (en) 1993-03-29
KR100253824B1 (ko) 2000-05-01
FI925615L (fi) 1993-06-13
NO302099B1 (no) 1998-01-26
ITRM920870A1 (it) 1994-06-04
DE4240430B4 (de) 2007-12-27
JPH05246844A (ja) 1993-09-24
CH684309A5 (de) 1994-08-31
CN1041794C (zh) 1999-01-27
AT401870B (de) 1996-12-27
AU661075B2 (en) 1995-07-13
IL104041A (en) 1998-12-27
FI114284B (fi) 2004-09-30
DK0547000T3 (da) 2000-06-26
ATA244992A (de) 1996-05-15
IL104041A0 (en) 1993-05-13
HU217629B (hu) 2000-03-28
GB2262229B (en) 1995-11-01
CY1994A (en) 1997-09-05
MX9207152A (es) 1993-07-01
EP0547000B1 (en) 2000-02-02
SK281710B6 (sk) 2001-07-10
HK25597A (en) 1997-03-06
AU3006992A (en) 1993-06-17
GR3032929T3 (en) 2000-07-31
ES2142819T3 (es) 2000-05-01
LU88201A1 (fr) 1994-09-09
DE4240430A1 (enExample) 1993-06-17
NZ245421A (en) 1995-11-27
JP2774037B2 (ja) 1998-07-09
CZ363392A3 (en) 1993-09-15
HUT63328A (en) 1993-08-30
NO924768L (no) 1993-06-14
GB2262229A (en) 1993-06-16
SK363392A3 (en) 1994-11-09
NO924768D0 (no) 1992-12-10
CN1091634A (zh) 1994-09-07
EP0547000A1 (en) 1993-06-16
RO111542B1 (ro) 1996-11-29
CA2085037C (en) 2000-11-28
US5356896A (en) 1994-10-18
PT547000E (pt) 2000-06-30
CA2085037A1 (en) 1993-06-13

Similar Documents

Publication Publication Date Title
RU2121835C1 (ru) Фармацевтическая композиция
US20050239884A1 (en) Compositions comprising hmg-coa reductase inhibitor
US6465477B1 (en) Stable pharmaceutical composition
CA2449998A1 (en) Stable controlled release pharmaceutical compositions containing pravastatin
US20120165386A1 (en) Stable oral pharmaceutial composition of atorvastatin
MXPA06005953A (es) Composiciones que comprenden compuestos organicos.
US20040180087A1 (en) Stable controlled release pharmaceutical compositions containing pravastatin
AU734787B2 (en) Method for producing medicaments containing HMG-CoA-reductase inhibitors
US20190070167A1 (en) Pitavastatin containing preparation and method for producing same
SA93130414B1 (ar) HMG-CoA Reductase التركيبات الدوائية الثابتة المشتملة على مركب مثبط لل
AU2002312297A1 (en) Stable controlled release pharmaceutical compositions containing pravastatin
AU2002314915A1 (en) Stable pharmaceutical compositions containing pravastatin